We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.88B
AUM Growth
-$822M
Cap. Flow
-$1.07B
Cap. Flow %
-15.57%
Top 10 Hldgs %
44.23%
Holding
173
New
23
Increased
20
Reduced
28
Closed
33

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$65.2M
2
PRCT icon
Procept Biorobotics
PRCT
+$63.6M
3
FOLD
Amicus Therapeutics
FOLD
+$35.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$31.4M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$93.6M
2
NVRO
NEVRO CORP.
NVRO
+$73.1M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$60.8M
4
MDT icon
Medtronic
MDT
+$55.9M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.92%
2 Financials 0.85%
3 Industrials 0.17%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
51
Xenon Pharmaceuticals
XENE
$6.1B
$30.9M 0.45%
2,022,051
+343,078
+20% +$5.96M
NVRO
52
DELISTED
NEVRO CORP.
NVRO
$30.3M 0.44%
259,972
-558,788
-68% -$73.1M
NUVB icon
53
Nuvation Bio
NUVB
$2.29B
$30.2M 0.44%
3,041,004
– –
HCAT icon
54
Health Catalyst
HCAT
$160M
$29.5M 0.43%
589,004
+22,920
+4% +$1.25M
LYRA
55
DELISTED
LYRA THERAPEUTICS INC
LYRA
$29.4M 0.43%
64,451
– –
TARS icon
56
Tarsus Pharmaceuticals
TARS
$2.55B
$27.9M 0.41%
1,296,416
– –
COGT icon
57
Cogent Biosciences
COGT
$6.76B
$26.8M 0.39%
3,188,750
– –
UTHR icon
58
United Therapeutics
UTHR
$26.1B
$26.2M 0.38%
141,700
-475,102
-77% -$93.6M
SLGC
59
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$25.4M 0.37%
+2,050,000
New +$23.1M
BCAB icon
60
BioAtla
BCAB
$5.34M
$25M 0.36%
17,001
+3,291
+24% +$6.41M
VRDN icon
61
Viridian Therapeutics
VRDN
$2.2B
$23.4M 0.34%
1,423,000
+628,494
+79% +$9.22M
RNAM
62
DELISTED
Avidity Biosciences
RNAM
$21.8M 0.32%
885,818
-193,210
-18% -$4.2M
CLDX icon
63
Celldex Therapeutics
CLDX
$2.94B
$21.3M 0.31%
393,613
-349,086
-47% -$16.4M
APLS
64
DELISTED
Apellis Pharmaceuticals
APLS
$20.3M 0.29%
615,000
-46,162
-7% -$2.59M
WGS icon
65
GeneDx Holdings
WGS
$1.89B
$19M 0.28%
75,758
+68,879
+1,001% +$23.7M
HRMY icon
66
Harmony Biosciences
HRMY
$2.08B
$18.8M 0.27%
491,332
– –
HLTH
67
DELISTED
Cue Health Inc. Common Stock
HLTH
$18.7M 0.27%
+1,580,607
New +$24.9M
IMRX icon
68
Immuneering
IMRX
$262M
$18.1M 0.26%
+681,051
New +$18.3M
NTRA icon
69
Natera
NTRA
$36.4B
$17.8M 0.26%
+160,000
New +$18.3M
TYRA icon
70
Tyra Biosciences
TYRA
$1.85B
$17.4M 0.25%
+987,500
New +$18.9M
ATXS
71
DELISTED
Astria Therapeutics
ATXS
$17.3M 0.25%
1,959,652
+678,454
+53% +$6.5M
ABSI icon
72
Absci
ABSI
$1.17B
$17.2M 0.25%
+1,476,776
New +$28.7M
NUVL
73
DELISTED
Nuvalent
NUVL
$16.9M 0.25%
+750,000
New +$21.8M
VRNA
74
DELISTED
Verona Pharma
VRNA
$15.8M 0.23%
2,888,889
– –
CCXI
75
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$15.8M 0.23%
+923,200
New +$14.4M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Perceptive Advisors held 173 positions worth $6.88B, down 11% from $7.71B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $1.07B in Q3 2021, closing 33 positions and reducing 28 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $60.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Icosavax, Inc. Common Stock worth $56.9M.

  • Perceptive Advisors's largest Q3 2021 buy was Icosavax, Inc. Common Stock: 1,922,549 shares worth $56.9M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q3 2021, an estimated $35.2M increase.
  • Perceptive Advisors's biggest Q3 2021 reduction was United Therapeutics, cutting an estimated $93.6M.
  • Perceptive Advisors fully exited Kadmon Holdings, Inc. in Q3 2021, selling an estimated $60.8M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $6.88B portfolio in Q3 2021.
  • Perceptive Advisors opened 23 new positions and closed 33 in Q3 2021.
  • Perceptive Advisors's portfolio value fell 11% quarter-over-quarter to $6.88B.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.